Essex Investment Management Co. LLC Buys Shares of 34,453 Ra Pharmaceuticals Inc (RARX)

Share on StockTwits

Essex Investment Management Co. LLC bought a new position in Ra Pharmaceuticals Inc (NASDAQ:RARX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 34,453 shares of the company’s stock, valued at approximately $623,000. Essex Investment Management Co. LLC owned about 0.11% of Ra Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. First Manhattan Co. increased its stake in Ra Pharmaceuticals by 38.1% in the 3rd quarter. First Manhattan Co. now owns 1,073,906 shares of the company’s stock valued at $19,426,000 after buying an additional 296,419 shares during the last quarter. Bank of America Corp DE increased its stake in Ra Pharmaceuticals by 513.2% in the 2nd quarter. Bank of America Corp DE now owns 43,436 shares of the company’s stock valued at $432,000 after buying an additional 36,352 shares during the last quarter. Citadel Advisors LLC increased its stake in Ra Pharmaceuticals by 5.7% in the 2nd quarter. Citadel Advisors LLC now owns 349,201 shares of the company’s stock valued at $3,475,000 after buying an additional 18,754 shares during the last quarter. Gabelli Funds LLC purchased a new stake in Ra Pharmaceuticals in the 2nd quarter valued at about $120,000. Finally, FMR LLC purchased a new stake in Ra Pharmaceuticals in the 2nd quarter valued at about $807,000. Institutional investors own 72.30% of the company’s stock.

Several equities research analysts have commented on RARX shares. Raymond James upgraded shares of Ra Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $28.00 price objective for the company in a research note on Wednesday, October 10th. Credit Suisse Group increased their price objective on shares of Ra Pharmaceuticals from $14.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, August 7th. Zacks Investment Research lowered shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 10th. BidaskClub lowered shares of Ra Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 5th. Finally, ValuEngine upgraded shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, September 27th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Ra Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $20.60.

Ra Pharmaceuticals stock opened at $16.64 on Friday. Ra Pharmaceuticals Inc has a twelve month low of $4.78 and a twelve month high of $19.43. The company has a market cap of $531.03 million, a PE ratio of -6.90 and a beta of 1.49.

Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Wednesday, August 8th. The company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.01. On average, sell-side analysts anticipate that Ra Pharmaceuticals Inc will post -2.14 earnings per share for the current fiscal year.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Story: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding RARX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ra Pharmaceuticals Inc (NASDAQ:RARX).

Institutional Ownership by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Horizonte Minerals  Hits New 1-Year Low at $0.03
Horizonte Minerals Hits New 1-Year Low at $0.03
Avivagen  Reaches New 12-Month Low at $0.42
Avivagen Reaches New 12-Month Low at $0.42
FrankyWillCoin  Price Reaches $0.0034 on Exchanges
FrankyWillCoin Price Reaches $0.0034 on Exchanges
Bitcoin Zero Price Tops $0.0239
Bitcoin Zero Price Tops $0.0239
Physicians Realty Trust  Expected to Post Quarterly Sales of $103.44 Million
Physicians Realty Trust Expected to Post Quarterly Sales of $103.44 Million
Analysts Set $17.55 Target Price for GreenTree Hospitality Group Ltd –
Analysts Set $17.55 Target Price for GreenTree Hospitality Group Ltd –


© 2006-2018 Ticker Report